Development of live attenuated influenza vaccines against pandemic influenza strains

Prime-Boost Interval Matters: A Randomized Phase 1 Study to Identify the Minimum Interval Necessary to Observe the H5 DNA Influenza Vaccine Priming Effect

(2013) Julie E. Ledgerwood, Kathryn Zephir, Zonghui Hu, Chih-Jen Wei, LeeJah Chang, Mary E. Enama, Cynthia S. Hendel, Sandra Sitar, Robert T. Bailer, Richard A. Koup, John R. Mascola, Gary J. Nabel, Barney S. Graham et al.   JOURNAL OF INFECTIOUS DISEASES

Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study

(2013) Marc Gurwith et al.   LANCET INFECTIOUS DISEASES

A postlicensure evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 24–59 months of age

(2013) Seth L. Toback et al.   VACCINE

An open-label phase I trial of a live attenuated H2N2 influenza virus vaccine in healthy adults

(2012) Kawsar R. Talaat et al.   Influenza and Other Respiratory Viruses

Effectiveness of 1 Dose of Influenza A (H1N1) 2009 Monovalent Vaccines in Preventing Reverse-Transcription Polymerase Chain Reaction-Confirmed H1N1 Infection Among School-Aged Children in Maine

(2012) A. Uzicanin et al.   JOURNAL OF INFECTIOUS DISEASES

A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 5 through 17 years of age

(2012) Roger Baxter et al.   VACCINE

The role of nasal IgA in children vaccinated with live attenuated influenza vaccine

(2012) Christopher S. Ambrose et al.   VACCINE

A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in adults 18–49 years of age

(2012) Roger Baxter et al.   VACCINE

Protective efficacy of live-attenuated influenza vaccine (multivalent, Ann Arbor strain): a literature review addressing interference

(2011) Allyn Bandell et al.   Expert Review of Vaccines

An integrated, multistudy analysis of the safety of Ann Arbor strain live attenuated influenza vaccine in children aged 2-17 years

(2011) Christopher S. Ambrose et al.   Influenza and Other Respiratory Viruses

Live and Inactivated Influenza Vaccines Induce Similar Humoral Responses, but Only Live Vaccines Induce Diverse T-Cell Responses in Young Children

(2011) Daniel F. Hoft et al.   JOURNAL OF INFECTIOUS DISEASES

DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials

(2011) Julie E Ledgerwood et al.   LANCET INFECTIOUS DISEASES

Effectiveness of Non-Adjuvanted Pandemic Influenza A Vaccines for Preventing Pandemic Influenza Acute Respiratory Illness Visits in 4 U.S. Communities

(2011) Marie R. Griffin et al.   PLoS One

WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: Supporting developing country production capacity through technology transfer

(2011) Martin Friede et al.   VACCINE

An open label Phase I trial of a live attenuated H6N1 influenza virus vaccine in healthy adults

(2011) Kawsar R. Talaat et al.   VACCINE

The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: A meta-analysis of 8 randomized controlled studies

(2011) Christopher S. Ambrose et al.   VACCINE

Immune responses to influenza virus infection

(2011) J.H.C.M. Kreijtz et al.   VIRUS RESEARCH

A Live Attenuated H7N7 Candidate Vaccine Virus Induces Neutralizing Antibody That Confers Protection from Challenge in Mice, Ferrets, and Monkeys

(2010) J.-Y. Min et al.   JOURNAL OF VIROLOGY

Safety and Immunogenicity Following Administration of a Live, Attenuated Monovalent 2009 H1N1 Influenza Vaccine to Children and Adults in Two Randomized Controlled Trials

(2010) Raburn M. Mallory et al.   PLoS One

Efficacy of a single dose of live attenuated influenza vaccine in previously unvaccinated children: A post hoc analysis of three studies of children aged 2 to 6 years

(2009) Stan L. Block et al.   CLINICAL THERAPEUTICS

A Live Attenuated H9N2 Influenza Vaccine Is Well Tolerated and Immunogenic in Healthy Adults

(2009) Ruth A. Karron et al.   JOURNAL OF INFECTIOUS DISEASES

Generation of Live Attenuated Novel Influenza Virus A/California/7/09 (H1N1) Vaccines with High Yield in Embryonated Chicken Eggs

(2009) Z. Chen et al.   JOURNAL OF VIROLOGY

Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in Humans

(2009)   NEW ENGLAND JOURNAL OF MEDICINE

A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults

(2009) Kawsar R. Talaat et al.   VACCINE

Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults

(2009) Ruth A. Karron et al.   VACCINE

Correlation of Cellular Immune Responses with Protection against Culture-Confirmed Influenza Virus in Young Children

(2008) B. D. Forrest et al.   Clinical and Vaccine Immunology

Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza

(2008) Christopher S. Ambrose et al.   Influenza and Other Respiratory Viruses

Immune Responses of Healthy Subjects to a Single Dose of Intramuscular Inactivated Influenza A/Vietnam/1203/2004 (H5N1) Vaccine after Priming with an Antigenic Variant

(2008) Nega Ali Goji et al.   JOURNAL OF INFECTIOUS DISEASES

Avian Influenza H6 Viruses Productively Infect and Cause Illness in Mice and Ferrets

(2008) L. Gillim-Ross et al.   JOURNAL OF VIROLOGY

Evaluation of Live Attenuated Influenza A Virus H6 Vaccines in Mice and Ferrets

(2008) Z. Chen et al.   JOURNAL OF VIROLOGY